Report an error

Spotted something inaccurate in “Evolocumab Cuts MACE Risk in Diabetic Patients Free of Known Atherosclerosis”? Tell us what’s wrong and we’ll check it against the original source.

Cancel

This form is for factual corrections. We read every report but cannot reply individually.